by Plus Therapeutics | Nov 19, 2024 | LM
Early Detection Saves Lives: Lung Cancer and Leptomeningeal Metastases Awareness Did you know that early detection of metastatic lung cancer can improve survival rates? This Lung Cancer Awareness Month, let’s take the opportunity to educate ourselves about the...
by Plus Therapeutics | Nov 18, 2024 | LM
Join Plus Therapeutics at the SNO Annual Meeting in Houston! Are you attending the 2025 Society for Neuro-Oncology (SNO) Annual Meeting in Houston this week? So are we! Plus Therapeutics is excited to showcase our latest research, symposium, oral presentations, and...
by Plus Therapeutics | Nov 8, 2024 | LM
You’re Invited: Symposium on Novel Targeted Radiotherapies for Leptomeningeal Metastases at the 2025 Society for Neuro-Oncology Annual Meeting in Houston Join Us at the SNO Annual Conference to Explore Groundbreaking Advances in Leptomeningeal Metastasis...
by Plus Therapeutics | Oct 29, 2024 | LM
Mark your calendars: We will be showcasing our Leptomeningeal Metastases programs at the 2024 SNO Annual Meeting in Houston, Texas! Plus Therapeutics will present data from the ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for leptomeningeal...
by Plus Therapeutics | Oct 2, 2024 | LM
COMING SOON 🎗️💓 In honor of #BreastCancerAwarenessMonth, we are excited to announce that we will be sharing a patient testimonial from one of our Metastatic Breast Cancer patients who was treated for Leptomeningeal Metastases through the ReSPECT-LM Clinical Trial. She...
by Plus Therapeutics | Aug 12, 2024 | LM
Highlights include: > Respect-LM dosing shows continued feasibility and safety of up to 44 mCi of intrathecal Rhenium (186Re) Obisbemeda > High absorbed radiation doses, mean circulating tumor cell reductions, and median overall survival of 12 months continue to...
Recent Comments